ARCT (Arcturus Therapeutics Holdings) EPS without NRI: $-2.83 (TTM As of Mar. 2026)


ARCT Arcturus Therapeutics Holdings Inc ARCT
56 GF Score
Price $7.27
GF Value $4.15
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Arcturus Therapeutics Holdings EPS without NRI?

Arcturus Therapeutics Holdings ARCT +5.67% 56 EPS without NRI is $-2.83 as of Mar. 2026. GuruFocus rates ARCT with a GF Score™ of 56/100 and a GF Value™ of $4.15 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,171 Biotechnology companies, Arcturus Therapeutics Holdings ranks worse than 85397.01% on this metric.

Arcturus Therapeutics Holdings's earnings per share without non-recurring items for the three months ended in Mar. 2026 was $-0.95. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.83.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Arcturus Therapeutics Holdings's EPS without NRI or its related term are showing as below:

During the past 13 years, Arcturus Therapeutics Holdings's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 52.70% per year. The lowest was -89.40% per year. And the median was 0.80% per year.

ARCT's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 16.8
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Arcturus Therapeutics Holdings's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.95. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.81.

Arcturus Therapeutics Holdings's EPS (Basic) for the three months ended in Mar. 2026 was $-0.95. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.81.


Arcturus Therapeutics Holdings  (NAS:ARCT) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Arcturus Therapeutics Holdings EPS without NRI Related Terms


Arcturus Therapeutics Holdings EPS without NRI Historical Data

* Premium members only.

The historical data trend for Arcturus Therapeutics Holdings's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arcturus Therapeutics Holdings EPS without NRI Chart

Arcturus Therapeutics Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.76 0.37 -2.12 -2.98 -2.41

Arcturus Therapeutics Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.52 -0.34 -0.48 -1.06 -0.95

ARCT vs MDWD, UNCY, EQ: EPS without NRI Comparison

For the Biotechnology subindustry, Arcturus Therapeutics Holdings's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arcturus Therapeutics Holdings PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcturus Therapeutics Holdings's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Arcturus Therapeutics Holdings's PE Ratio without NRI falls into.


ARCT
56GF Score
Arcturus Therapeutics Holdings Inc ARCT
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arcturus Therapeutics Holdings EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $-2.83 mean?
Arcturus Therapeutics Holdings (ARCT) has a EPS without NRI of $-2.83 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Arcturus Therapeutics Holdings and its competitors. According to the industry distribution chart, Arcturus Therapeutics Holdings ranks #999999 out of 1171 companies in the Biotechnology industry.
Is Arcturus Therapeutics Holdings' EPS without NRI too high?
Arcturus Therapeutics Holdings' current EPS without NRI is $-2.83. Based on the distribution chart, Arcturus Therapeutics Holdings ranks #999999 out of 1171 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Arcturus Therapeutics Holdings has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcturus Therapeutics Holdings' EPS without NRI compare to MDWD and UNCY?
According to the Biotechnology industry distribution chart, Arcturus Therapeutics Holdings ranks #999999 out of 1171 companies for EPS without NRI. This places Arcturus Therapeutics Holdings in the lower half of its industry. The industry median EPS without NRI is 16.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.80, based on 1,171 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Arcturus Therapeutics Holdings and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcturus Therapeutics Holdings's current EPS without NRI is $-2.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcturus Therapeutics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings (ARCT) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.15, compared to a current price of $7.27 — trading 75.2% above its estimated fair value. The current EPS without NRI is $-2.83. Arcturus Therapeutics Holdings' overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Arcturus Therapeutics Holdings (ARCT), the current EPS without NRI is $-2.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arcturus Therapeutics Holdings (ARCT) Overvalued in 2026?

Based on GuruFocus' analysis, Arcturus Therapeutics Holdings stock appears to be overvalued. The current stock price of $7.27 is trading 75.2% above its estimated GF Value™ of $4.15. GuruFocus considers Arcturus Therapeutics Holdings to be Significantly Overvalued.

Key valuation signals for ARCT:

  • EPS without NRI: $-2.83
  • GF Value™: $4.15 vs. price of $7.27 (75.2% above fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the ARCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Arcturus Therapeutics Holdings Business Description

Address 10285 Science Center Drive, San Diego, CA, USA, 92121
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
56GF Score

Get the complete analysis for ARCT

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.27
Price
$4.15
GF Value